Registration
XOMA CORPORATION (FKA XOMA (US) LLC) for XOMA CORPORATION (FKA XOMA (US) LLC)
Income
—
Expenses
—
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Science/Technology SCI
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Defense DEF
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Disaster Planning/Emergencies DIS
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Manufacturing MAN
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Health Issues HCR
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Pharmacy PHA
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Homeland Security HOM
No issues at present time
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN CAFARO New | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE New | President CEO |
| PATRICK JEROME SCANNON New | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ New | Vice President, Operations and Biodefense Business |
Affiliated organisations
| Organisation | Location |
|---|---|
| BUCHANAN INGERSOLL & ROONEY PC | Washington, DC, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.